Evidence map›Paper›PMID 34532389›Full record

ArticleAnnals of translational medicine2021

High BTBD7 expression positive is correlated with SLUG-predicted poor prognosis in hormone receptor-negative breast cancer.

Zi-Xiong Li, Ze-Nan Huang, Hui Luo, Xiong-Bin Yang, Yu-Lin Wang, Jie-Xin Chen, Xiao-Kai Ma, Feng Xu, Tian-Tian Wang, Ling Lin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Zi-Xiong LiDepartment of Rheumatology, The First Affiliated Hospital, Shantou University Medical College, Shantou, China.
Ze-Nan HuangDepartment of Thyroid and Breast Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Hui LuoAnesthesia and Operation Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiong-Bin YangDepartment of Rheumatology, The First Affiliated Hospital, Shantou University Medical College, Shantou, China.
Yu-Lin WangDepartment of Neurosurgery, First Affiliated Hospital, Shantou University Medical College, Shantou, China.
Jie-Xin ChenDepartment of Endocrinology, First Affiliated Hospital, Shantou University Medical College, Shantou, China.
Xiao-Kai MaThe first affiliated Hospital of Bengbu Medical College, Bengbu, China.
Feng XuClinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Tian-Tian WangDepartment of Medical Oncology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ling LinDepartment of Rheumatology, The First Affiliated Hospital, Shantou University Medical College, Shantou, China.
Shantou University · CNFirst Affiliated Hospital of Shantou University Medical College · CNSun Yat-sen University · CNFirst Affiliated Hospital of Bengbu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHormone receptor-negative breast cancer (HRNBC), which includes triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER-2) overexpressing breast cancer, is prone to metastasis and has a poor prognosis. BTB/POZ domain-containing protein 7 (Btbd7) is thought to regulate SLUG and the epithelial-mesenchymal transition (EMT) process. However, the role of Btbd7 in HRNBC is unclear.

methodsExpression of BTBD7 and SLUG in HRNBC tumor tissue and normal adjacent tissue (NAT) as well as breast cancer cells were characterized by immunohistochemistry and immunofluorescence. MDA-MA-231 cells was transfected with BTBD7 siRNA and detected by qRT-PCR and western blot. Expression levels of Slug and EMT related proteins were detected western blot analysis. cell invasion assays were used to analyse cell invasion ability of MDA-MA-231. GO and KEGG analyses was used to analysis the gene function.

resultsThe total positive rate of BTBD7 expression in HRNBC tumor tissue was 66.7%, which was higher than that in NAT (52.1%) and benign breast lesion tissues (20%). Co-expression of SLUG and BTBD7 proteins could be found in HRNBC tissue and MDA-MA-231 cells.

conclusionsThe study data indicated that BTBD7 was inversely associated with SLUG expression. Higher BTBD7 was associated with poor clinicopathologic features and prognosis in HRNBC patients.

Indexed as

BTB/POZ domain-containing protein 7 (BTBD7)epithelial-mesenchymal transition (EMT)hormone receptor negative breast cancer (HRNBC)SLUG

Identifiers

PMID34532389
PMCPMC8421947
OpenAlexW3118415249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.